Xanomeline

Jake Nichols, a pharmacist in recovery, highlights the challenges of substance use disorders in the profession. A phase 3 trial shows positive results for obinutuzumab in treating lupus nephritis. The FDA approves xanomeline and trospium chloride for schizophrenia, marking a new treatment option. Chronic pain in youth is linked to higher anxiety and depression, according to a study. Novo Nordisk's CEO agrees to negotiate lower list prices for semaglutide drugs with PBMs.

Bristol Myers Squibb announces FDA approval of COBENFY™ (xanomeline and trospium chloride), the first new pharmacological approach to treat schizophrenia in decades, targeting M1 and M4 receptors without blocking D2 receptors. Supported by the EMERGENT clinical program, COBENFY demonstrated significant symptom reduction in schizophrenia patients.

FDA approved Cobenfy, a new schizophrenia treatment targeting cholinergic receptors, offering an alternative to traditional antipsychotics with fewer side effects. Expected to be available in late October, it costs $1,850 per month.

FDA approves Cobenfy (xanomeline and trospium chloride) for schizophrenia in adults, offering a new treatment option with fewer side effects compared to traditional antipsychotics. Cobenfy targets cholinergic receptors, not dopamine, and clinical trials showed significant symptom reduction. Common side effects include constipation, nausea, and dizziness.

FDA approves dupilumab for COPD, xanomeline and trospium chloride for schizophrenia, levacetylleucine for Niemann-Pick disease type C, FluMist for self-administered flu prevention, benralizumab for eosinophilic granulomatosis with polyangiitis, lebrikizumab-lbkz for atopic dermatitis, OTC hearing aid software for mild to moderate hearing loss, DaylightRX for generalized anxiety disorder, a disposable insulin patch pump for T1D and T2D, and an updated Novavax COVID-19 vaccine.

FDA approves Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in 30 years, targeting cholinergic receptors. Cobenfy, priced at $22,500/year, is expected to be widely covered by mid-2025, offering a new alternative to current antipsychotic medications. The approval opens opportunities for other drugs in the market.

The FDA approved Bristol Myers Squibb’s Cobenfy for treating schizophrenia in adults, marking the first new class of medication for the condition in decades. Cobenfy demonstrated significant reductions in schizophrenia symptoms in trials, with common adverse events being gastrointestinal-related. The approval offers a new pharmacological approach to managing schizophrenia.

The FDA approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, marking the first in a new class targeting M1 and M2 receptors without blocking D2 receptors. Supported by the EMERGENT clinical program, Cobenfy demonstrated a statistically significant 8.4-point reduction in PANSS scores compared to placebo, with generally well-tolerated safety profile.

FDA approves Bristol Myers Squibb's Cobenfy, the first novel schizophrenia treatment in 70 years, targeting muscarinic receptors to reduce dopamine activity without typical antipsychotic side effects. Expected to launch in late October at $22,500/year, with potential peak U.S. sales of $2 billion by 2030.